Incretin‐Based Therapies in Alzheimer's and Parkinson's Disease: Advancing Neuroprotection With Dual and Triple Agonists—A Review
ABSTRACT Background Alzheimer's disease (AD) and Parkinson's disease (PD) are progressive neurodegenerative disorders with significant cognitive and motor impairments, affecting millions globally. Current treatments offer limited efficacy, prompting the exploration of new therapeutic appro...
Saved in:
| Main Authors: | Ousman Mohammed, Tsehayneh Kelemu |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-07-01
|
| Series: | Health Science Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/hsr2.71065 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Emerging concepts in obesity management: focus on glucagon receptor agonist combinations
by: Sarah L Anderson
Published: (2025-07-01) -
Pharmalogical effects and results of clinical trials of the first incretinomimetic exenatide
by: Alexander Sergeevich Ametov, et al.
Published: (2011-09-01) -
GLP-1 receptor agonists in Parkinson’s disease: an updated comprehensive systematic review with meta-analysis
by: Mohamed Mohsen Helal, et al.
Published: (2025-08-01) -
The C-terminal regions of the GLP-1 and GIP receptors are not the key determinants of their differential arrestin recruitment but modulate the rate of receptor endocytosis
by: Bashaier Al-Zaid, et al.
Published: (2025-03-01) -
Glucagon-Like Peptide-1 and Hypothalamic Regulation of Satiation: Cognitive and Neural Insights from Human and Animal Studies
by: Joon Seok Park, et al.
Published: (2025-05-01)